Literature DB >> 32075091

Accelerated Partial Breast Irradiation: Macrophage Polarisation Shift Classification Identifies High-Risk Tumours in Early Hormone Receptor-Positive Breast Cancer.

Sören Schnellhardt1, Ramona Erber2, Maike Büttner-Herold3, Marie-Charlotte Rosahl1, Oliver J Ott1, Vratislav Strnad1, Matthias W Beckmann4, Lillian King5, Arndt Hartmann2, Rainer Fietkau1, Luitpold Distel1.   

Abstract

Studies have demonstrated correlations between accumulations of tumour-associated macrophages (TAMs), especially of M2-like phenotype, and increased mortality in advanced breast cancer. We investigated the prognostic potential of both main macrophage phenotypes in early hormone receptor-positive (HR+) breast cancer. The studied cohort of 136 patients participated in an institutional APBI phase II trial. Patient selection was characterized by HR+, small tumour size and no metastasis. Tissue microarrays from pre-RT resection samples were double stained for CD68/CD163 using immunohistochemistry. CD68+/CD163- cells were considered M1-like macrophages and CD68+/CD163+ was representative of M2-like macrophages. M1 and M2 macrophage densities were analysed semi-automatically in the stromal and intraepithelial tumour compartment. Low M1 and high M2 densities were strongly associated with decreased disease-free survival (DFS). Combined TAM phenotype densities were studied after defining a macrophage shift classification: M1-shifted (M1 high, M2 low) and non-shifted (M1 low, M2 low; M1 high, M2 high) tumours entailed a favourable outcome. In contrast, M2-shifted (M1 low, M2 high) TAM populations were associated with extremely reduced DFS. Thus, the full predictive potential of TAMs was revealed in a combined analysis of both phenotypes. The M2-shifted subgroup of tumours is classified as high-risk and probably not suitable for partial breast irradiation.

Entities:  

Keywords:  CD163; CD68; accelerated partial breast irradiation; early breast cancer; hormone receptor-positive; prognosis; tumour associated macrophages

Year:  2020        PMID: 32075091     DOI: 10.3390/cancers12020446

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  8 in total

1.  The Prognostic and Predictive Significance of Tumor-Infiltrating Memory T Cells Is Reversed in High-Risk HNSCC.

Authors:  Rebekka Hartan; Sören Schnellhardt; Maike Büttner-Herold; Christoph Daniel; Arndt Hartmann; Rainer Fietkau; Luitpold Distel
Journal:  Cells       Date:  2022-06-17       Impact factor: 7.666

Review 2.  Role of Tumor-Associated Myeloid Cells in Breast Cancer.

Authors:  Yoon Jin Cha; Ja Seung Koo
Journal:  Cells       Date:  2020-07-27       Impact factor: 6.600

Review 3.  Personalized Nutrition as a Key Contributor to Improving Radiation Response in Breast Cancer.

Authors:  Anuradha A Shastri; Joseph Lombardo; Samantha C Okere; Stephanie Higgins; Brittany C Smith; Tiziana DeAngelis; Ajay Palagani; Kamryn Hines; Daniel A Monti; Stella Volpe; Edith P Mitchell; Nicole L Simone
Journal:  Int J Mol Sci       Date:  2021-12-24       Impact factor: 5.923

4.  Factors related to the suppression of the antitumour immune response in female dogs with inflammatory mammary carcinoma.

Authors:  Karine Araújo Damasceno; Aline Michelle Dos Santos-Conceição; Laís Pereira Silva; Thiago Marconi de Souza Cardoso; Carlos Humberto da Costa Vieira-Filho; Samantha Hellen Santos Figuerêdo; Emanoel Martins-Filho; Barbra Gabriela Oliveira de Faria; João Moreira da Costa-Neto; Geovanni Dantas Cassali; Alessandra Estrela-Lima
Journal:  PLoS One       Date:  2022-05-05       Impact factor: 3.752

5.  Tumour-Infiltrating Inflammatory Cells in Early Breast Cancer: An Underrated Prognostic and Predictive Factor?

Authors:  Sören Schnellhardt; Ramona Erber; Maike Büttner-Herold; Marie-Charlotte Rosahl; Oliver J Ott; Vratislav Strnad; Matthias W Beckmann; Lillian King; Arndt Hartmann; Rainer Fietkau; Luitpold Distel
Journal:  Int J Mol Sci       Date:  2020-11-03       Impact factor: 5.923

6.  M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer.

Authors:  Masanori Oshi; Yoshihisa Tokumaru; Mariko Asaoka; Li Yan; Vikas Satyananda; Ryusei Matsuyama; Nobuhisa Matsuhashi; Manabu Futamura; Takashi Ishikawa; Kazuhiro Yoshida; Itaru Endo; Kazuaki Takabe
Journal:  Sci Rep       Date:  2020-10-06       Impact factor: 4.379

7.  Immunohistochemical analysis of PD-L1 and tumor-infiltrating immune cells expression in the tumor microenvironment of primary signet ring cell carcinoma of the prostate.

Authors:  Qi-Liang Teng; Xin-Rui Yang; Shuang Wen; Zhi-Hong Dai; Hong-Long Wang; Tian-Qing Liu; Liang Wang; Bo Fan; Zhi-Yu Liu
Journal:  Asian J Androl       Date:  2022 Sep-Oct       Impact factor: 3.054

8.  Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.

Authors:  Liuning Li; Guojie Lu; Yang Liu; Longlong Gong; Xue Zheng; Hongbo Zheng; Weiguang Gu; Lin Yang
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.